Navigation Links
BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
Date:10/22/2007

SAN ANTONIO, Oct. 22 /PRNewswire/ -- BioMedical Enterprises, Inc. (BME), a privately held medical device company and leader in orthopedic shape memory implant technology, today announced that the U.S. Food and Drug Administration (FDA) has given 510(k) marketing clearance to the OSSpine(TM) for use in anterior fixation of the cervical spine to provide enhanced biomechanical stability & bone graft retention. The patent-pending OSSpine(TM) builds on the extremity bone fusion success of BME's OSStaple(TM) and OSSplate(TM), and joins the Step OSStaple(TM) and the OSSArc(TM) dynamic residual compression implants as the most recent additions to BME's OSSforce(TM) Fixation System.

Made of nitinol, a biocompatible alloy possessing shape memory and super-elastic properties, the OSSpine(TM) implant is inserted while in its malleable state at room temperature. Using BME's patent-pending OSSforce(TM) Implant Controller, the implant is safely heated to activate its shape change and impart compression forces across the fusion site. During this process, the implant's legs close and it's s-shaped back shrinks providing uniform compression while the alloy's structure transforms into a state approximately 20% stronger then 316L stainless steel. The OSSpine(TM) implant actively compresses the fusion construct compensating for any graft subsidence that may occur during healing.

BME recently announced that it had received a Notice of Allowance from the United States Patent and Trademark Office for 61 claims providing protection for their innovative OSSforce(TM) Implant Controller technology. The OSSpine(TM) implants and the OSSforce(TM) Implant Controller will be showcased by BME at the North American Spine Society (NASS) 22nd Annual Meeting being held October 23-27, 2007 in Austin, Texas.

BioMedical Enterprises, Inc. (BME) is a medical device company that addresses the changing needs in musculoskeletal medicine. BME focuses on minimally invasive orthopaedic instrumentation and implants that elicit a biologic response. BME's focus on memory metal internal fixation implants is changing the shape of orthopaedic medicine. Its specialized history of musculoskeletal research services will continue to produce unique, state of the art orthopaedic products that provide better outcomes for patients and more convenience to surgeons. For more information visit http://www.bme-tx.com.


'/>"/>
SOURCE BioMedical Enterprises, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical engineering conference invites manufacturers
2. Manufacturing partnership will move into biotech and biomedical spaces
3. Biomedical Alliance about more than stem cells
4. Doyle seeks $2.5M for biomedical alliance
5. Students will show off biomedical devices to professors and investors
6. Biomedical alliance marks first full year
7. UW Biomedical Engineering awarded $2.9 million research grant
8. Having two biomedical tech centers in Wisconsin will help the state
9. New biomedical institute aims to unite business and academia in SE Wisconsin
10. Wisconsin publicly traded biomedical companies report gains this quarter
11. Medical College receives $377K to study brain disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):